Search Results

SELUTION DeNovo and SELUTION4ISR Studies Evaluate Cordis’ Selution SLR DEB 

October 26, 2025—Results of two studies evaluating the performance of the Selution SLR sirolimus drug-eluting balloon (DEB; Cordis) were presented in a late-breaking clinical trials session at the TCT 2025 scientific symposium.

FDA Approves IDE to Study CeloNova's Cobra PzF Coronary Stent

March 18, 2014—CeloNova BioSciences, Inc. (San Antonio, TX) announced that the US Food and Drug Administration (FDA) has granted approval to start an investigational device exemption (IDE) trial for its Cobra PzF coronary stent system.

Enrollment Complete in SHIELD Trial of CeloNova's Cobra PzF Stent

February 19, 2015—CeloNova BioSciences, Inc. announced completion of patient enrollment in the global, multicenter PzF SHIELD trial for its Cobra PzF stent, which features a nano-thin coating of Polyzene-F (PzF) polymer.

MedAlliance Commences IDE Trial of Selution SLR 014 DCB to Treat In-Stent Restenosis

July 7, 2020—MedAlliance announced enrollment of the first patient in its study of the Selution SLR 014 for the treatment of in-stent restenosis (ISR).

FDA Approves Expansion of CeloNova's COBRA REDUCE Trial

October 26, 2017—CeloNova BioSciences, Inc. announced that the US Food and Drug Administration (FDA) approved expansion of the company's ongoing clinical trial of its Cobra Polyzene-F (PzF) nanocoated coronary stent (NCS) with 14-day dual antiplatelet therapy (DAPT) in complex patients, such as those who are at high bleeding risk.

CeloNova Announces Clinical Results From Pivotal PzF SHIELD Trial

February 2, 2017—CeloNova BioSciences, Inc. recently announced the publication of primary endpoint results from its global, multicenter PzF SHIELD clinical trial evaluating the company's Cobra Polyzene-F (PzF) nanocoated coronary stent.

Early Data Presented From First-in-Man Study of CeloNova's Cobra PzF Stent

September 16, 2014—CeloNova BioSciences, Inc. announced that results from its first-in-man clinical trial showed that the company’s Cobra PzF coronary stent system, which features a cobalt chromium super alloy and a nanothin coating of the company’s Polyzene-F polymer, is a safe and effective routine interventional treatment for real-world and complex patients with heart disease.

FDA Approves CeloNova's Cobra PzF Stent System

March 1, 2017—CeloNova BioSciences, Inc. announced US Food and Drug Administration approval of its Cobra PzF polyzene-F nanothin polymer-coated coronary stent system.

First Results Presented From Pivotal US Study of the Tryton Side Branch Stent

October 30, 2013—Tryton Medical, Inc. (Durham, NC) announced that the first results from the TRYTON pivotal investigational device exemption (IDE) coronary bifurcation trial of the Tryton side branch stent, a dedicated bifurcation device, were presented during a late-breaking clinical trial session at the TCT 2013: Transcatheter Cardiovascular Therapeutics conference in San Francisco, California.